We would love to hear your thoughts about our site and services, please take our survey here.
"The AViDD centers will conduct research on the early-stage identification and validation of novel viral targets ............ the most promising will enter late-stage preclinical development. Importantly ........ making use of the companies’ chemical libraries and expertise in moving candidates into the product development pipeline."
Certainly sounds 'right up our street' ... 'Novel', 'anti-viral', 'home-setting'. On the cusp of A2P3 we are surely ready for early movement into, 'the product development pipeline', so is this a potential rationale for FDA to at least consider EUA if we have this kind of support and a 'PT' on the way.
Despite the upcoming 25/5 update, A2P2 results will surely be our real signpost. My only thoughts then are, what a re-started A2P3 (fingers-crossed emoji) looks like - perhaps a more focussed target audience and therefore a hope of similar P3 DD-type high %'s. So, looking forward my related questions are these:
1. Is there really a need for a further PT, if we secure A2P3?, - I would hope no, and
2. If, in their excitement, SNG accept another PT invite, do we risk additional delay or further 'muddying of the waters' where both results even in part contradict each other (e.g. P2 & P3) .. in simple terms, can too many PT's be counter-productive? - I'm thinking yes, possibly.
Matt ... agree, and I particularly liked the 'nod' from P. Monk, COS, in the RNS to testing wider that just Covid patients and showing the full potential of SNG ... as per the last part of his last sentence ...
"These results provide a strong clinical rationale to continue to investigate SNG001 in a trial evaluating progression and/or mortality in hospitalised patients with COVID-19 ...... and more widely in patients with severe viral lung infections."
.. if you are listening in here.
Opening the ATS presentations with good positive news of a novel, broad spectrum, anti-viral therapeutic should be an early conference 'hit' and hopefully leave the audience wanting more.
Whilst ATS starts tomorrow, if the 'team' are keeping their powder dry until they present Mon (16th) my bet is, that the (required) RNS - assuming price sensitive (new) info emerges then - will arrive Mon 07.00, a few hours ahead of their presentation. I can only guess their argument (like anyone having presented at a conference) is that you work on what you are actually going to say until the last minute. That said, I'm even happier if it comes tomorrow. All just out-loud thoughts as we sit nervously in the RNS 'waiting room'.
If you are invested then, of course we all, either openly or to ourselves, seek out anything positive to salve the lingering pain of our current lowly ranking. So, considering SNG's (more usual) 'under promise over deliver' ethos, it would seem reasonable to expect a renewed caution from them after their more buoyant language that preceded Feb 21st. This, if we must pontificate, should bode well where we feel compelled to pour over both word and tone of the upcoming ATS. Well, I hope so anyway.
Nice find - very interesting ... could this experience (including SNG P3) become a more recognised 'thing', and therefore gain some traction and better understanding ... maybe even with early mention at ATS ... I certainly hope so.
Likewise to previous comments ref welcome return by pmjh, and the resultant raising of the bar generally in the discussions. Thanks as alway to all other valued commentators. We all need to 'inhale' some well-reasoned positivity and hope now and again. Fwiw, I personally regularly review my initial, and still relevant, reasons for investing several years ago and then, more substantially, from March 2020.
Can't see it but apologies if already posted.
https://t.co/WvV3wRi88q
https://twitter.com/AIMdective/status/1517037386701717509?t=pqAMi4aWA3erKIWHtulORQ&s=19
Let me jump in and just stay that it is now reasonable to assume everyone knows where most regular posters stand. It would be good (for everyone's sanity) to move on, look forward and discuss what's coming up, not what's already gone down. It's clear that chat has understandably reduced on here and I for one get a lot more out than I put in and would not want it to dry up completely. However, whilst we have different views we really want the same thing, so we're just preaching to the converted here when it comes to how we got to where we are. Thanks again for those still researching and posting new stuff.
Another good find TommyD ... Just to add the last part of the conclusion ...
"Several studies investigating the use of IFN-based agents in viral respiratory infections, including for SARS-CoV-2, are ongoing, signaling the potentially promising role of IFN-based agents in mitigating future viral respiratory epidemics."
The is the interesting question, and one imho, that surely must have a different answer today than it did on 20 Feb, namely that SNG's baby (now a troublesome teenager) needs some help to grow into a promising (commercial) adult. So, any plans to go it alone may now be tempered with accepting the help of a JV to make sure this happens. RM & SSH are not exactly at the start of their careers and this may be the compromise to ensure that their dreams are realised.